Stock Market Reviews

GLSI (Greenwich LifeSciences, Inc.) News

Get the latest news, insights, and market updates on GLSI (Greenwich LifeSciences, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
  STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to March 31, 2026 which is approximately 66 mon
  Mar 27, 2025 - $GLSI
• Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
  STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label safety data. FLAMINGO-01 Data Safety Monitoring Board (DSMB) The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recom
  Mar 17, 2025 - $GLSI
• 55% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is owned by insiders, and they've been buying recently
  Key Insights Significant insider control over Greenwich LifeSciences implies vested interests in company growth 53% of...
  Mar 5, 2025 - $GLSI
• Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01
  STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label HLA data. Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A p
  Feb 10, 2025 - $GLSI
• EMA approves addition of sites to Greenwich LifeSciences’ breast cancer trial
  The approved expansion will allow the activation of nearly 110-115 sites throughout Europe.
  Jan 30, 2025 - $GLSI
• Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe
  STAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the expansion of the clinical trial into Europe. The Company's application to add an additional 11 sites in Spain, Germany, and Poland has been formally approved by EM
  Jan 29, 2025 - $GLSI